A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy.
Antoniou
Tony
T
Park-Wyllie
Laura
L
Boyle
Eleanor
E
D000328:Adult; D018791:CD4 Lymphocyte Count; D002784:Cholesterol / Q000097:blood; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000139:chemically induced*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D019469:Indinavir / Q000009:adverse effects* / Q000627:therapeutic use; D061466:Lopinavir; D011744:Pyrimidinones / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D019438:Ritonavir / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D019562:Viral Load
D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D014280:Triglycerides; D061466:Lopinavir; D019469:Indinavir; D002784:Cholesterol; D019438:Ritonavir